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Summary A randomised study was conducted in 62 patients with advanced breast cancer to assess whether
granulocyte-macrophage colony-stimulating factor (GM-CSF) would yield an increase in the dose intensity of
a standard-dose CEF regimen through an acceleration ofchemotherapy administration. Patients received CEF
(cyclophosphamide 600 mgm'2, epidoxorubicin 60mg m-2 and fluorouracil 600 mg m-2) i.v. on day 1 or the
same chemotherapy, plus GM-CSF 1Olg kg-I s.c. starting from day 4, repeated as soon as haematopoietic
recovery from nadir occurred. Patients in the CEF + GM-CSF group received chemotherapy at a median
interval of 16 days compared with 20 days in the control group. This led to a significant increase (P = 0.02) in
the dose intensity actually administered in the third, fourth and sixth cycles: +28%, +25%, +20%
respectively. Non-haematological toxicity was mild. GM-CSF had to be reduced or suspended in 50% of
patients because of toxicity. Haematological toxicity, mainly cumulative anaemia and thrombocytopenia, was
manageable. An increase in response rate for patients with measurable disease, of borderline statistical
significance (P= 0.088, P for trend = 0.018), from 42% in the CEF group to 69% in the CEF + GM-CSF
group, was observed. This randomised trial indicates that GM-CSF is useful for chemotherapy acceleration.
Accelerated CEF + GM-CSF is a moderately dose-intensive regimen that can be administered in an outpatient
clinic and is associated with a high objective response.
No dramatic improvements in the treatment of metastatic
breast cancer have been achieved in the last decade. First-line
standard combination chemotherapy induces objective remis-
sions in 40-70% of patients, but only 10-20% of these
responses are complete. No cure has been achieved and
overall survival has not been modified, being still 24 months
on average. However, this lack of progress does not reflect a
plateau in research efforts. New drugs, ideas and strategies
have been developed and tested in the clinical setting. Among
these, the role of dose intensity, defined as the amount of
drug given per unit time, has been extensively debated
(Hryniuk et al., 1984; Henderson et al., 1988). Arguments for
and against its relevance are based essentially on retrospec-
tive analyses (Hryniuk et al., 1984; Bonadonna et al., 1981)
or on randomised trials that were actually designed to test
standard vs low dose intensity rather than standard vs high
dose intensity regimens. Analysis of results from randomised
studies testing the value of the dose or dose intensity, without
bone marrow support, clearly reveals that myelosuppression
is the dose-limiting factor hindering the administration of
higher than standard dose intensities. However, the recent
availability of haematopoietic colony-stimulating factors
(CSFs), a family of glycoproteins that support the prolifera-
tion and differentiation of haematopoietic progenitors, could
overcome this limitation. Phase I and II trials have been
conducted by using granulocyte-macrophage and granulo-
cyte CSF (GM-CSF and G-CSF) alone or in combination
with chemotherapy. These studies have indicated the ability
of GM-CSF and G-CSF to reduce the severity of leucocyte
nadir and to shorten the duration of leucopenia after stan-
dard chemotherapy (Demetri et al., 1992; Kaplan et al.,
1991). These findings have led to the incorporation of GM-
CSF and G-CSF in chemotherapy programmes in an attempt
to increase the dose intensity without the need for bone
marrow and/or peripheral stem cell transplantation. Three
possible means to increase dose intensity can be considered:
increasing the dose, shortening the interval between cycles or
a combination of both. Among these, we have chosen to
pursue the second. The scientific rationale of this strategy
stems from the observation that, by using G-CSF or GM-
CSF, leucocyte nadir is anticipated and recovery hastened,
while the depth of the nadir is only slightly affected (Hoek-
man et al., 1991; Logothetis et al., 1990; Gabrilove et al.,
1988; Hamm et al., submitted). Pilot studies carried out in
patients with small-cell lung carcinoma (Ardizzoni et al.,
1990, 1993) suggest that GM-CSF is indeed able to allow an
increase in the frequency of chemotherapy administration.
However, the amount of dose intensity increase achievable is
only around 30% and the question may be posed as to
whether the growth factor is really needed to obtain such an
increase in dose intensity. Therefore, before starting ran-
domised trials aimed at assessing the clinical impact of
chemotherapy acceleration, it seemed important to verify, in
a prospective randomised fashion, whether this type of dose
intensity increase would actually require the concomitant use
of GM-CSF.
Based on previous experiences carried out at the Istituto
Nazionale per la Ricerca sul Cancro of Genoa (Conte et al.,
1987; 1990), a combination of cyclophosphamide, 5-fluorour-
acil and epidoxorubicin (CEF) was chosen to address this
question in advanced breast cancer.
The primary objective of the study was to compare the
CEF dose intensity achieved with and without GM-CSF.
Since chemotherapy doses were the same in both groups, the
study was designed to test whether the addition of GM-CSF
would allow a significant increase in CEF dose intensity
through an acceleration of chemotherapy administration.
Secondary objectives of the study were to compare the two
treatment groups in terms of both toxicity and anti-tumour
activity.
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Patients and methods
Eligibility
Eligible patients were women aged 18-65 years with histo-
logically confirmed stage IlIb or IV (AM Joint Committee,
1981) carcinoma of the breast. Patients who had received
prior chemotherapy for advanced disease or patients who
had finished adjuvant chemotherapy less than 12 months
before randomisation were not eligible for the study. Prior
hormonal therapy and prior limited radiotherapy (involving
no more than 30% of the functioning bone marrow) were
permitted.
Eligible patients were also required to have a WHO perfor-
mance score <3 and to be mentally and geographically
suitable for the study. Patients with clinical or radiological
evidence of brain metastases, those who were pregnant and
those who had previously been treated with haemopoietic
growth factors were excluded. Additional eligibility criteria
included adequate haematological [white blood cells (WBC)
> 3 x I09 1' and/or absolute neutrophil count (ANC) >2 x
I09 I-' , platelet (PLT) > 100 x I09 I-' and haemoglobin level
(Hb)>9.5 g dl-'], renal (creatinine level < 1.4 mgdl-') and
hepatic (bilirubin level > 1.4 mg dl-') function, adequate car-
diac function (no clinical evidence of congestive heart failure,
symptoms ofcoronary artery disease, serious cardiac arrhyth-
mias, prior myocardial infarction on ECG or pericarditis)
and no evidence of active infection.
Study design and treatment
Patients were randomised to receive a chemotherapy regimen
consisting of cyclophosphamide (CTX) 600 mg m-2, epidoxo-
rubicin (EpiDX) 60 mg m-2 and 5-fluorouracil (FU) 600 mg
m-2 given by intravenous bolus on day 1 on an ambulatory
basis or the same chemotherapy combined with GM-CSF
(Schering-Plough/Sandoz) self-administered subcutaneously
at a dose of 10 tg kg-' from day 4 (because of the long
plasma clearance of EpiDX) until adequate haematopoietic
recovery (WBC > 3 x I09 Il and/or ANC >2 x 109 1-h', PLT
> 100X 1091' and Hb>9.5 g dl-'). In both groups the time
of recycle was not fixed but chemotherapy had to be repeated
as soon as haemopoietic recovery occurred. In patients
receiving GM-CSF, 1 day's rest was required between the last
growth factor administration and the next chemotherapy
course. In patients in whom nadir haematological toxicity did
not occur, a minimum interval between chemotherapy
courses of 10 days had to be observed.
A 25% chemotherapy dose reduction, in subsequent
courses, was considered only in the case of grade IV non-
haematological toxicity or in case of grade IV haematological
toxicity associated with one of the following complications:
anaemia with heart failure, febrile neutropenia or document-
ed infection, bleeding.
In metastatic patients, chemotherapy was continued for at
least six courses unless progressive disease or life-threatening
toxicity occurred. A further four courses could be given in
responsive patients at the discretion of the investigator to
achieve a maximum of ten chemotherapy cycles or chemo-
therapy was continued until best response was achieved plus
two courses. Locally advanced patients were treated with
induction chemotherapy until best response was reached,
with a maximum of six cycles, then radical surgery was
performed, if indicated.
Prophylactic ciprofloxacin 500 mg b.i.d. was recommended
in patients with WBC<I x 1091l or ANC<0.5 x 1091-l.
PLT transfusions were given when PLT count felt below
30 x 109 and red blood cell transfusions with Hb values
below 9 g dl-'. The use of corticosteroids was allowed only
as antiemetic treatment during chemotherapy administration.
Paracetamol was administered whenever required to control
bone pain and fever induced by GM-CSF. HI antagonists
were given to patients with allergic reactions related to GM-
CSF administration. In case of grade III-IV toxicity attri-
butable to GM-CSF, the growth factor was first withdrawn
until side-effects subsided and then resumed at a dose of
5 tLg kg-'. Whenever, despite the dose reduction, toxicity was
still present, GM-CSF was suspended and chemotherapy
continued outside the protocol.
The study was accepted by the Protocol Review Committee
of the Istituto Nazionale per la Ricerca sul Cancro and of
each collaborating centre. Informed consent was verbally
obtained from all the patients before study entry. The study
was carried out at the Istituto Nazionale per la Ricerca sul
Cancro of Genoa and in four other collaborating institutes.
Monitoring
At the start of therapy patients underwent history and
physical examination, including tumour measurement, chest
radiographs, complete blood count and serum chemistry,
tumour markers, liver ultrasound, bone nuclear scan, ECG
and bone marrow aspiration and/or biopsy. During treat-
ment patients were required to have a complete blood count
at least twice a week. Serum chemistries and tumour markers
were repeated every two cycles, while chest radiography, liver
ultrasound and bone nuclear scan were repeated every 2-3
cycles if needed for response assessment. Bone marrow
aspiration/biopsy was repeated at the end of treatment only
in patients with documented bone marrow metastases. Vital
signs were checked before and 2 h after the first GM-CSF
dose, which had to be administered in the outpatient clinic.
Criteria oftumour response and toxicity
Tumour responses and toxicities were assessed according to
WHO criteria (Miller et al., 1981).
As tumour response was not the primary focus of the
study, both patients with and without measurable disease
were randomised. Therefore, tumour response was evaluated
only in patients with measurable disease, and comparison of
responses in the two treatment groups was limited to these
patients.
Time to progression and overall survival were calculated
from the first day of treatment.
Statistics and dose intensity calculation
Randomisation was obtained by telephoning the Trial Office
of the Istituto Nazionale per la Ricerca sul Cancro of
Genova. Patients were stratified by institution only.
The main objective of the study was to compare the dose
intensity achieved in the two treatment groups. Dose inten-
sity, expressed in mg m-2 day-', was calculated for each drug
as the total amount of drug given in mg divided by the body
surface area and by the time in days elapsed between the
start of the treatment and the day of the last chemotherapy
course. Reference standard dose intensity was that of an
equivalent regimen (same doses, same drugs) delivered at
3-week intervals. It was arbitrarily planned to perform dose
intensity calculations at the third, fourth and sixth cycles.
Patients receiving > 130% of the standard dose intensity
were considered as successes; all the others were defined as
failures.
In analysing dose intensity results an 'intent to treat'
criterion was applied. Therefore all patients were evaluated
including those who in whom GM-CSF administration was
reduced or suspended. Patients who did not receive at least
two cycles of chemotherapy were excluded from the dose
intensity calculation, but considered for statistical analysis as
failures.
Fixing a = 0.05 and J = 0.10, and defining PI as the pro-
portion of successes in the control group and P2 as the
expected proportion of successes in the experimental group,
the total number of patients to be accrued was calculated, for
a two-tailed z-test for the comparison of proportions, based
on the following considerations. It was estimated that in
approximately one-third of the patients it is possible to
administer the regimen being studied without GM-CSF at
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cycle. The doubling of this proportion appeared to be the
minimal target worth detecting in this trial to justify further
studies testing the clinical efficacy of such a dose intensity
increase with GM-CSF in breast cancer patients. Therefore,
setting PI to 0.35 and P2 to 0.70, the number of patients
needed for this study was 92.
Owing to difficulties in obtaining drugs, analysis of results
was done after 60 patients has been accrued. At this time, as
a lower than expected proportion of successes was observed
in the control group, it was decided to stop the accrual since
the study had sufficient power to detect the target difference
(33% difference in the proportion of successes). No adjust-
ment for repeated analysis was planned.
Results
From July 1990 to April 1992, 62 patients entered the study.
Their main characteristics are shown in Table I. Thirty
patients were assigned to CTX, EpiDX and FU (CEF), and
32 patients to the same treatment plus GM-CSF (CEF +
GM-CSF).
Four patients were not evaluated for toxicity and dose
intensity calculation: two patients, one in each group, drop-
ped out immediately after randomisation, and two patients in
the CEF group received only one cycle of chemotherapy (one
patient died from disseminated intravascular coagulation,
another refused to continue chemotherapy). These four
patients were recorded as failures for dose intensity analyses
according to the study protocol. One additional patient was
not evaluable for toxicity because of missing data.
In seven other patients in the CEF group and 11 patients
in the CEF + GM-CSF group therapy was stopped before
the sixth cycle. Reasons for stopping were as follows: in the
CEF group five cases of progressive disease (PD) and two
clinician's decisions [stable disease (SD) at the fourth and
fifth cycles]; in the CEF + GM-CSF group three PD, seven
clinician's decisions (2 SD after five cycles, and five IIIB
patients who had undergone mastectomy) and one case of
GM-CSF-related toxicity.
Dose intensity analysis
Overall, 346 cycles were given: 159 and 187 cycles of CEF
and CEF + GM-CSF respectively. Patients in the two groups
Table I Patient characteristics
CEF (%) CEF+ GM-CSF (%)
Entered 30 (100) 32 (100)
Age (years)
<50
50-60
>50
Performance status
0
1-2
Stage
Illb
IV
Dominant site of metastases
Visceral ±other sites
Soft tissue± bone
Bone alone
Histology
Ductal
Lobular
Medullary
Unknown
Prior adjuvant chemotherapya
Yes
No
Bone marrow involvement
Yes
No
Inadequate material
9 (30.0)
11 (36.7)
10 (33.3)
19 (63.4)
11 (36.6)
4 (13.3)
26 (86.7)
15 (57.7)
6 (23.0)
5 (19.2)
22 (73.3)
5 (16.7)
3 (10.0)
0
10 (38.5)
16 (61.5)
4 (13.3)
24 (80.0)
2 (6.7)
aIn patients presenting with stage IV.
13 (40.6)
10 (31.3)
9 (28.1)
26 (81.2)
6 (18.8)
8 (25.0)
24 (75.0)
17 (70.8)
5 (20.8)
2 (8.3)
21 (65.7)
5 (15.6)
5 (15.6)
1 (3.1)
10 (41.7)
14 (58.3)
4 (12.5)
25 (78.1)
3 (9.4)
received the same median number of cycles (six) and almost
the same median cumulative dose of chemotherapy. A similar
percentage of patients in the two treatment groups had at
least three, four or six cycles of therapy (Table II). A
significant difference in median dose intensity actually admin-
istered was observed: by the third, the fourth and the sixth
cycles patients treated with GM-CSF received, respectively,
28%, 25% and 20% higher dose intensity than CEF patients
(Figure 1). This increase in dose intensity was entirely due to
the acceleration of chemotherapy in the group of patients
receiving GM-CSF. In fact, cycles were given at a median
interval of 16 days instead of 20 days (Table II). Moreover,
this difference was maintained across cycles. The median
interval between cycles was constantly lower in the CEF +
GM-CSF arm: 15 vs 19 days for the first cycle, 15 vs 20 days
for the third cycle, up to 17 vs 21 days for the sixth cycle.
According to the study protocol, patients receiving at least
a 30% increase in the actual dose intensity, compared with
the planned dose intensity of a standard CEF given every 21
days at the same doses, were considered as successes. Analys-
ing results at the third, fourth and sixth cycles, both on all
randomised patients and on patients who actually received
the treatment, a significantly higher number of successes in
CEF + GM-CSF arm was recorded (Figure 2). In particular,
at the sixth cycle only two patients (6.7%) in the CEF group
satisfied the criteria of success, compared with ten patients
(31.2%) in the CEF + GM-CSF group (P= 0.034). This
difference was also statistically significant when only patients
actually on therapy at that time were evaluated (P = 0.020).
A logistic regression analysis of factors predicting the pro-
bability of success was performed. The only independent
factor significantly affecting dose intensity outcome was the
assigned treatment, with patients receiving GM-CSF having a
higher chance of achieving a dose intensity success at the
Table II Cycles and dose results
CEF+ GM-CSF
CEF (range) (range) P
Median no. of cycle 6 (1 -9) 6 (3- 10) NS
Median interval (days) 20 (8-36) 16 (7-49) 0.001
Patients receiving at least
Three cycles 27/30 (90.0%) 31/32 (96.8%) NS
Four cycles 25/30 (83.3%) 28/32 (87.5%) NS
Six cycles 20/30 (66.6%) 20/32 (62.5%) NS
Median total dosea
CTX (mg) 5700 5544
(1,000-6,690) (2,700-7,500)
EpiDX (mg) 570 540 NS
(100-660) (270-750)
FU (mg) 5700 5544
(1,000-6,690) (2,700-7,500)
aAt the sixth cycle. NS, not significant.
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Figure 1 Increase in dose intensity of CEF ( _ ) and CEF plus
GM-CSF (=II) compared with a standard CEF (CEF 21)
administered every 21 days ( ).
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sixth cycle. On the other hand, performance status, age, prior
adjuvant chemotherapy, stage, histology and bone marrow
involvement at entry were not important determinants of
dose intensity in our study.
Chemotherapy toxicity and GM-CSFsafety
The incidence and degree of the most common toxicities are
listed in Table III. Toxicity was fully evaluated in 57 patients,
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Figure 2 Rate of success at the third, the fourth and the sixth
cycle. a, All patients i.e. all randomized patients. b, Evaluable
patients, i.e. patients who actually received three, four or six
cycles. -, CEF; =, CEF + GM-CSF.
28 in the CEF group and 29 in the CEF + GM-CSF group,
and across 327 courses of therapy, 157 and 170 respectively.
Treatment-related toxicity was mild and consisted mostly of
myelosuppression. Only one episode of grade IV non-haema-
tological toxicity (one case of mucositis in the GM-CSF
group) occurred. Alopecia was virtually universal. Among
gastrointestinal toxicities, nausea was reported by nearly all
patients, while vomiting was generally mild and occurred in a
minority of patients. Patients in the CEF + GM-CSF group
had a significantly higher prevalence of fatigue: 51 out of 170
(30%) cycles were associated with some degree of tiredness.
In CEF + GM-CSF and CEF groups nearly 50% and 90%
patients, respectively, never experienced fatigue (P = 0.0015).
Fifty per cent of patients required dose reduction or
suspension of GM-CSF because of side-effects. Nine patients
withdrew from the drug: of these, five patients after pre-
liminary 50% (5ytg kg-1) dose reduction and the other four
patients without any preliminary dose reduction. In seven
patients the dose of GM-CSF was reduced to 5 ytg kg-' and
then the planned treatment continued. Virtually all patients
had local erythema and mild pain or discomfort at the site of
injection. Only one 'first-dose reaction' was observed (des-
cribed in Lieschke et al., 1989). The main toxic effects related
to GM-CSF were fever, flu-like symptoms, hypotension,
headache, bone pain and diffuse cutaneous rash.
Haematological toxicity was recorded at nadir. Leucopenia
did not significantly differ between the two groups: two-
thirds of the patients had grade III-IV leucopenia. However,
few courses of therapy were associated with grade IV leuco-
penia: 1.9% (3/157) in the CEF group and 11.1% (19/170) in
the other group (P<0.05). The median nadir was almost
identical (2,150 x 106 1-1 and 2,175 x 106 1-l in the CEF and
CEF + GM-CSF groups respectively), and remained substan-
tially unmodified with subsequent courses (Figure 3).
In contrast, a statistically significant difference in thrombo-
cytopenia and anaemia was observed. Nearly 32% of patients
receiving CEF plus GM-CSF vs 7.1% in the CEF group had
grade III/IV thrombocytopenia which was life-threatening
(grade IV) in 14% and 0% of cases respectively. Moreover,
27.5% of patients in the CEF + GM-CSF group suffered
from anaemia vs 3.5% in the CEF group. In the GM-CSF
group, 43.4% cycles were associated with any grade of
platelet toxicity, as compared with 19.5% in the CEF arm.
Furthermore, thrombocytopenia and anaemia progressively
worsened with increasing cycles of therapy in the CEF +
GM-CSF group (Figure 3). The median PLT nadir was
nearly identical at the first cycle, 143 vs 145 x 109I`, CEF vs
CEF + GM-CSF, but was clearly different at the sixth cycle,
154 vs 66.5 x 109 1-'. Nevertheless, only one patient required
platelet transfusions. Conversely, the cumulative anaemia led
to a significant increase in transfusion requirements: six
blood units (CEF group) vs 43 blood units (GM-CSF group).
However, despite considerable haematological toxicity in
Table III Percentage of worst-ever toxicity by patient
CEF CEF+ GM-CSF
0 I-II III-IV 0 I-II III-IV
Nausea/vomiting 25.0 67.8 7.1 17.2 62.0 20.6
Mucositis 78.6 17.8 3.5 62.0 31.0 6.8
Cystitis 96.4 3.5 - 96.5 3.4
Leucopenia 3.5 28.5 67.8 10.3 20.6 68.9
Thrombocytopenia 57.1 35.7 7. la 37.9 31.0 31.oa
Anaemia 42.8 53.6 3.5b 17.2 55.1 27.5b
Fatigue 92.8c 3.5d 3.5 51.7c 34.4d 13.7
Alopecia 3.5 14.2 82.1 6.8 10.3 82.7
Bone pain 96.4 3.5 - 75.8 20.6 3.4
Headache - - - 82.7 17.2
Hypersensitivity - - - 72.4 24.1 3.4
Anorexia - - - 86.2 13.7
Fever - - - 44.8 51.7 3.4
Flu-like symptoms - - - 62.0 34.4 3.4
Hypotension - - - 86.2 13.7
ap = 0.041, Fischer's exact test. bp = 0.025, Fischer's exact test. cP = 0.0015, chi-squared test.
dp = 0.008, chi-squared test.
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patients treated with growth factors, only two hospitalisa-
tions were necessary because of febrile neutropenia, and no
death from toxicity occurred.
Tumour response and survival
Since measurable disease was not required as an entry
criterion, the evaluation of response was performed only in
patients with measurable tumour at the beginning of the
study. Fifty-three patients were included in this analysis
(Table IV). There was evidence of an advantage in terms of
objective responses (CR + PR) in the CEF + GM-CSF
group, 68.9% (95% CI 49-85%) vs 41.6% (95% CI 22-
63%), of borderline statistical significance (response vs no
response: X for heterogeneity = 2.89, P = 0.088; test for trend
over four strata of response: X for trend = 5.55, P = 0.018).
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The effect of age, performance status, stage, bone marrow
invasion, dominant site of metastases, adjuvant therapy and
assigned treatment (CEF vs CEF + GM-CSF) on response
were analysed by a logistic regression procedure. The only
two variables found to be independently associated with the
probability of objective response were stage (coefficient
-2.1 ± 1.2, P = 0.02) and treatment group (coefficient 1.3 ±
0.7, P = 0.05).
Median time to progression was 11 months for CEF and
14 months for CEF + GM-CSF (P = 0.41). So far 15 patients
(50%) in the CEF group and nine patients (28.1%) in the
CEF + GM-CSF group have died. The former had a median
actuarial survival of 17 months. Median actuarial survival in
GM-CSF arm has not been reached yet. The actuarial 2-year
survival is 40% (95% CI 18-62%) and 67% (95% CI 49-
85%) for CEF and CEF + GM-CSF respectively (X = 2.13,
P=0.14).
500 ~~~~~~~~~~~Discussion
DOO The availability of haematopoietic growth factors for clinical
50oo use has generated considerable excitement among oncolo-
)OO0 gists, who believe that these growth factors will allow the safe
administration of more intensive, and hopefully more
500 P =not significant effective, treatments without the need for sophisticated bone
0 1 1 J ~~~~~marrow replacement procedures. 0
2 4 5 6 Until now, randomised studies have proved that both GM- 1 23 4 5 6 ~~~~~CSFand G-CSF are able to reduce the morbidity associated
with standard chemotherapies (Hamm et al., submitted;
14 -b Crawford et at., 1991; Trillet-Lenoir et at., 1993). The same
13 -studies also indicate that CSFs, by preventing dose reduc-
12 - * * tions and delays in chemotherapy, allow the delivery of dose
11 intensities which are closer to those projected by the protocol
10 compared with the control. However, no randomised trial
9 ~~~~~~~~~~~~has thus far been conducted to assess whether CSFs allow
7 the safe administration of doses or dose intensities higher
6 than those achievable with standard protocols. The results of P0.-24a few pilot studies performed (Bronchud et at., 1989; Hoek-
4 man et at., 1991) are indeed dismal in this respect, since the
1 2 3 4 5 6 occurrence of cumulative haematological toxicities and unex-
pected non-haematological toxicities prevented a significant
180 - dose intensity escalation. A possible explanation for this
160 ~~~~~~~~~~~failure could be the fact that, although G-CSF and GM-CSF 60 ~~~~~~~~~~~~~are able to accelerate leucocyte recovery after chemotherapy,
140 -they cannot abrogate nadir leucopenia and have no effect on
120 -other haemopoietic lineages.
100 Pilot studies carried out by our group in SCLC have
indicated that a dose intensity increase can also be accom-
80 plished by acclerating chemotherapy administration in
60 -P=0.024 combination with GM-CSF (Ardizzoni et at., 1990; 1993).
40 - However, in this case also, dose intensity can be augmented
1 2 3 4 5 6 only to a limited extent and for a limited number of cycles
Cycles owing to the occurrence of cumulative haematological tox-
icities. Therefore doubt arises about the real need for GM-
3Median a, WBC; b, Hb; and c, PLT nadir counts CSF to obtain such a result. Our randomised trial is helpful
,ycles. -,CEF; Li, CEF + GM-CSF. in clarifying this issue. The addition of GM-CSF allowed
breast cancer patients to receive GEE every 16 days instead
of every 20 days as in the control group: this corresponds to
a 20% increase in dose intensity with respect to the control
Table IV Response to treatment group and to a 27% increase with respect to CEF given every
r, LI ~~~~~21 days. Chemotherapy acceleration was seldom possible in CEF CEF + GM-CSF patients not receiving the growth factor. A multivariate
No. (% No. (% analysis provided further evidence that the administration of
response 2/24 (8.3) 6/29 (20.7) GM-CSF is the only variable affecting the dose intensity
iponse 8/24 (33.3) 14/29 (48.3) delivered. Although the increase in dose intensity achieved
responsea 10/24 (41.6)b 20/29 (68.9)c with the use of growth factor was limited, it has to be noted
that dose intensity calculations were made on the entire
ease 7/24 (29.2) 7/29 (24.1) patient population, including those who had to withdraw
re disease 4/24 (16.7) 2/29 (6.9) from GM-CSF ('intent to treat' analysis). In addition, abled 3/24 (12.5) 0/29 because of the fear of a possible interaction between the
)88 (P for trend =0.018). b95% CI 22-63. C95% CI 49-85. growth factor and an anti-cancer drug with long plasma
)rnon-evaluation: twopatients refused treatmentand one was clearance such as epidoxorubicin, GM-CSF was started only
low-up. on day 4. This late start might have led to an underestima-
1
1
1
1
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tion of the true clinical activity of GM-CSF in allowing
accelerated delivery of chemotherapy.
The long-term feasibility of acclerated CEF could also be
demonstrated by the number of cycles administered. In fact,
two-thirds of patients managed to receive at least six courses
of chemotherapy, in both CEF and GM-CSF groups. The
efficacy of GM-CSF in sustaining leucocyte recovery was
constant throughout treatment. Despite the acceleration of
chemotherapy achieved in the patients treated with GM-CSF,
the median leucoycte nadir did not differ in the two groups
in any of the chemotherapy courses.-On the contrary, most
patients on GM-CSF developed cumulative anaemia and
thrombocytopenia. This phenomenon has also been described
in other studies (Hoekman et al., 1991; Hamm et al., submit-
ted; Ardizzoni et al., 1993). However, unlike previous
reports, these toxicities were always manageable on an out-
patient basis. Only one patient required platelet transfusion.
Treatment with accelerated chemotherapy and GM-CSF was
associated with a significantly higher incidence of moderate
fatigue. This could be explained either by the acceleration of
treatment itself or by the higher degree of anaemia and
GM-CSF-related symptoms. Overall, toxicities related to the
growth factor required dose reduction or suspension in 50%
of patients. When we planned the study, the chosen dose of
10ltgkg-' was based on the fact that this dose had proved
safe and effective in our previous pilot studies on accelerated
chemotherapy (Ardizzoni et al., 1990; 1993). More recent
data (Hamm et al., submitted) and results from the present
study would indicate that the dose of 5ttgkg-' might be
preferable in addition to moderately dose-intensive pro-
grammes. The issue of dose intensity impact on the clinical
outcome of breast cancer patients is still a matter of contro-
versy. Hryniuk and Bush (1991) first observed in a retrospec-
tive study the direct correlation between dose intensity and
clinical outcome in advanced breast cancer. We are aware of
at least 11 randomised trials that have prospectively explored
the role of dose or dose intensity in advanced breast cancer
(Tannock et al., 1988; Habeshaw et al., 1991; Carmo-Peirera
et al., 1987; Hoogstraten et al., 1976; O'Bryan et al., 1977;
Forastiere et al., 1982; Beretta et al., 1986; Hortobagyi et al.,
1987; Ebbs et al., 1989; Becher et al., 1990; Focan et al.,
1990). Seven of these, actually addressed the value of stan-
dard, or almost standard, doses of chemotherapy compared
with low doses (Tannock et al., 1988; Habeshaw et al., 1991;
Carmo-Peirera et al., 1987; Hoogstraten et al., 1976; O'Bryan
et al., 1977; Forastiere et al., 1982; Focan et al., 1990). All
but one highlighted an advantage in terms of response rate in
standard dose arms, but none of these assessed the true role
of dose intensity. In fact, analysing data from three studies
with more than 100 patients each, two (Tannock et al., 1988;
Focan et al., 1990) did not report any data about total dose
delivered, while in the third (Habeshaw et al., 1991), the
significant increase in median dose intensity reported was
associated with a significant increase in median total dose. A
study conducted at the M.D. Anderson Clinic (Hortobagyi et
al., 1987), in which patients were randomised to receive a
standard FAC or an escalated FAC (fluorouracil, adria-
mycin, cyclophosphamide) utilising a protected environment,
failed to detect any difference either in response rate or in
survival. This study is generally claimed as an example of
failure of dose intensity, but it errs for the above-mentioned
reason: the median dose, expressed in mg m-2 per cycle, was
different in the two groups. Moreover, a subsequent analysis
by the same authors (Hortobagyi et al., 1989) showed no
significant difference in the dose intensity actually delivered,
at 24 weeks, between high and standard dose arms. Indeed, it
is not possible to assess the importance of cumulative dose
independently of dose intensity. Experimental results (Skip-
per, 1990) indicate that cumulative dose and dose intensity
may have independent and different effects. Therefore, to test
the role of dose intensity it is important that planned and
actual total administered dose are the same in both the
control and the experimental groups of the study. This
criterion was met in our study, in which patients in both
groups received the same cumulative dose of chemotherapy
and the same numbers of cycles.
The moderate increase in dose intensity obtained by accle-
rating CEF chemotherapy yielded an increase in response
rate of borderline statistical significance. In addition, this
response rate was higher than that obtained in two prior
consecutive randomised trials carried out in our Institute
(Conte et al., 1987; 1990). When adjusted for prognostic
factors, treatment retained its significant effect on response
rate. Noteworthy was the fact that the effect of the dose
intensity could be analysed without other confounding fac-
tors such as schedule, cumulative dose or drugs utilised.
However, since anti-tumour response was not the primary
objective of the study and given the small sample size, this
result should be considered with caution.
In conclusion, the present study demonstrates that, with
GM-CSF support, acceleration of the CEF regimen can be
accomplished, achieving an almost 30% increase of dose
intensity over the standard schedule. CEF acceleration is
feasible and haematological toxicity is manageable for at
least six courses in an outpatient setting.
We thank Laura Stele and Monica Guelfi for careful data managing.
This study was supported jointly by Schering-Plough Corporation,
AIRC grant and CNR Grant No. 93.02275-PF39 (ACRO).
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